Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Different dosing strategies of sugammadex in morbidly obese patients undergoing laparoscopic bariatric surgery
ChiCTR2000040720Phase 4Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Dec 2020
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of Sugammadex in neuromuscular block (NMB) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Time to TOF ratio 0.9. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
Sugammadex
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on ChiCTR2000040720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040720.